Market requirements · NO
Norway
Norway applies the legemiddelloven and criminalises trade in listed doping substances under the general penal code rather than under sports rules alone. Classification follows function and presentation rather than product description, and the regulator has published that a peptide presented for injection is a medicinal product. Norway sits in the EEA and in Schengen but outside the EU customs union, so most EU medicines law applies while every consignment from the EU still clears Norwegian customs and attracts Norwegian import VAT.
| Tell us the compounds you need for Norway. | Ask about Norway |
The regime
How compounds are classified in Norway
| Governing law | The governing instrument is the legemiddelloven, LOV-1992-12-04-132, last amended with effect from 1 July 2026. Section 13 governs import, section 14 wholesale dealing and section 24a possession of doping substances. The operative regulations are the Legemiddelforskriften, which carries the definition of a medicinal product, and the Forskrift om grossistvirksomhet med legemidler, last amended with effect from 1 January 2025. The regulator is Direktoratet for medisinske produkter, formerly Statens legemiddelverk. |
|---|---|
| What determines classification | There is no positive substance list to clear a product against. The Forskrift om legemiddelklassifisering and its lists were repealed on 1 July 2020 after EU case law held that lists cannot be the sole basis for classification, so the regulator decides product by product on function and presentation. Its published checklist states that products intended for injection are regarded as medicinal products unless they fall under medical device or cosmetics rules, and that a product containing a substance covered by the doping regulations always falls under the doping rules. In a notice dated 5 May 2026 the regulator set out the working rule plainly: taken orally a peptide is generally a food supplement, applied to skin a cosmetic, and injected a medicinal product. That same notice names "For Research Use Only" as a disclaimer used by selling websites rather than a classification. |
| EEA but outside the EU customs union | The EU pharmaceutical framework applies in Norway through the EEA Agreement, including Directive 2001/83/EC and the European good distribution practice guidelines, and an EEA manufacturer or wholesaler can trade into Norway on notification rather than a fresh Norwegian licence. The customs side does not follow. The Norwegian government states that the EEA Agreement does not cover the EU customs union, so a shipment from an EU member state is an import: it must be declared to Tolletaten, and although most goods carry no duty the declaration is mandatory and VAT applies on import at 25 per cent. Free trade agreements do not cover VAT. Schengen membership governs the movement of persons and removes none of these formalities for goods. |
| Doping offences | Straffeloven section 234 punishes with a fine or up to two years anyone who unlawfully manufactures, imports, exports, stores, sends or transfers a substance treated as a doping agent, and section 235 raises a gross offence to six years. Bare possession is caught separately, by legemiddelloven section 24a, which forbids acquiring, possessing or using a listed substance without lawful access. A business holding stock is caught by storage under section 234. The official list is the dopingliste annexed to FOR-1993-04-30-318 and it extends beyond the named substances to their salts, derivatives, isomers, esters and ethers, and to any preparation containing them. Named entries include somatropin and growth hormone, the insulin-like growth factors, the mechano growth factors, the gonadotropins and erythropoietin. |
| Enforcement posture | Active on both sides. Tolletaten reported in June 2026 that it had made over 800 seizures of illegal peptides so far that year, against about 1,040 in 2025 and 620 in 2024, named China as the main sending country, and said doping seizures in particular can lead to a criminal complaint. The regulator published its own warning on 5 May 2026 stating that these products are not approved medicines, that import is unlawful and that selling and marketing them is prohibited. Tolletaten also publishes that it is the Norwegian regulator's classification, and not the sending country's, that decides the point. |
| Already supplying Norway? Send the compounds and volumes you buy today and we will quote against them. | Send your list |
Your obligations
What a buyer in Norway needs settled
- Hold a grossisttillatelse from Direktoratet for medisinske produkter before importing from any EEA state, storing, distributing or exporting anything the regulator would classify as a medicinal product.
- Hold a separate approval for import from outside the EEA, and verify on the published registers that every supplier and buyer actually holds the permission it claims.
- Screen every product against the dopingliste, including salts, derivatives, isomers, esters and ethers, before any consignment leaves the supplier, because import, storage, sending and transfer of a listed substance is a criminal offence.
- Assume anything presented for injection is a medicinal product unless it is a CE-marked device or a cosmetic, and do not rely on research-use wording, which the regulator has publicly called a seller's disclaimer.
- Register in the Merverdiavgiftsregisteret once VAT-liable turnover exceeds NOK 50,000 in twelve months, declare every consignment to Tolletaten, and report import VAT at 25 per cent in your own return.
- Keep records of every inbound and outbound transaction with date, product, quantity, counterparty and batch number, available to the supervisory authority for at least five years.
We will ask about this at enquiry. We check the authorisations your activity requires before quoting, and we confirm the position per compound rather than for the market as a whole.
Sources
Check this yourself
Every position above traces to a dated public document. The authority, the document, the date and the link are below.
| Authority and document | Date | Link |
|---|---|---|
| Direktoratet for medisinske produkter Advarer mot peptider til injeksjon, warning on injectable peptides | 2026 | www.dmp.no/nyheter/advarer-mot-peptider-til-injeksjon |
| Direktoratet for medisinske produkter Er produktet et legemiddel, classification checklist | 2026 | www.dmp.no/godkjenning/klassifisering |
| Lovdata Lov om legemidler m.v. (legemiddelloven), LOV-1992-12-04-132 | 1992, as amended 2026 | lovdata.no/dokument/NL/lov/1992-12-04-132 |
| Lovdata Lov om straff (straffeloven), sections 234 and 235, doping offences | 2005, as amended | lovdata.no/dokument/NL/lov/2005-05-20-28/KAPITTEL_2-8 |
| Lovdata Forskrift om hva som skal anses som dopingmidler, FOR-1993-04-30-318, with the dopingliste | 1993, as amended 2013 | lovdata.no/dokument/SF/forskrift/1993-04-30-318 |
| Lovdata Forskrift om grossistvirksomhet med legemidler, FOR-1993-12-21-1219 | 1993, as amended 2025 | lovdata.no/dokument/SF/forskrift/1993-12-21-1219 |
| Tolletaten Importguide, Norwegian customs import guidance | 2026 | www.toll.no/no/bedrift/import/importguide |
| Tolletaten Import av legemidler og urter, permit required and classification decided in Norway | 2026 | www.toll.no/no/varer/legemidler-og-kosttilskudd/import_av_... |
Links go to the issuing body wherever one exists. Positions change. If you are relying on any of this, check the source rather than this page.
Market brief
Take the Norway brief as a PDF
The regime, the buyer obligations and all 8 sources, dated and linked, in one document you can forward.
Same region
Nordics
Buyers supplying one of these usually supply the others. The requirements are not the same.
| Code | Market | Sources | |
|---|---|---|---|
| DK | Denmark | 5 sources | Laegemiddelstyrelsen maintains standing warnings, including on Melanotan. Rese... |
| SE | Sweden | 5 sources | Lakemedelsverket has a published position on Melanotan II, and a government-co... |
| FI | Finland | 2 sources | Fimea has warned against injectable peptides sold through social media. Semagl... |
| IS | Iceland | 6 sources | Iceland applies the Medicinal Products Act No. 100/2020, administered by the I... |
Scope
How to use this page
A summary of the published regulatory position in Norway as at 2026-08-20, written for procurement teams deciding how to source. Every source is dated and linked so it can be checked at origin.
It is not legal advice. Full terms of supply, including where responsibility sits, are set out in our terms of supply.
Questions
Supplying into Norway
Do you supply into Norway?
We supply businesses that hold the authorisations their activity requires. Whether a specific compound can be supplied into Norway depends on that compound and on your authorisations, and we confirm it per compound at the enquiry stage.
Who carries the compliance obligation?
The importer of record and the party placing the product on the market, which is the buyer. We supply the batch documentation that supports your file. We cannot hold your authorisations for you.
How current is this page?
It was reviewed on 2026-08-20 and is scheduled for review again on 2026-11-18. Every source is dated and linked, so you can check the original.
We already supply into Norway. What changes if we source from you?
The batch documentation. You receive a Certificate of Analysis per batch, which can be issued under your own brand. The import and market-placing responsibilities stay where they are.
Is this legal advice?
No. It is a summary of the regulatory positions those authorities have published, as at the review date above. Take advice in your own market before you rely on it.
Enquire about supply into Norway
Tell us the compounds and your authorisations. We confirm per compound before anything ships.